Researchers found that a new treatment combination, involving a drug called gedatolisib, has shown significant promise for patients with a specific type of advanced breast cancer. This treatment, which combines gedatolisib with fulvestrant and palbociclib, demonstrated improved progression-free survival compared to standard therapies in patients with hormone receptor positive, HER2 negative, and PIK3CA mutant breast cancer. This is particularly relevant for those who have not responded well to previous treatments.

For individuals facing advanced breast cancer, these findings could mean better outcomes and more effective treatment options. The study focused on patients whose cancer had progressed after receiving other therapies, a group that often struggles with limited treatment success. The results indicate that the combination therapy could significantly extend the time before the cancer worsens, which is a critical factor in managing advanced cancer and improving quality of life.

The evidence comes from a Phase 3 clinical trial, which is a robust stage of testing that typically includes a larger number of participants. This trial specifically evaluated the effectiveness of gedatolisib in patients with PIK3CA mutations, a genetic change found in about 40% of hormone receptor positive, HER2 negative breast cancer cases. While the results are promising, they are still pending full regulatory approval, and the drug’s effectiveness will need to be confirmed through further studies.

If you or someone you know is dealing with advanced breast cancer, it may be worth discussing these new treatment options with your healthcare provider, especially if previous therapies have not been effective. Staying informed about emerging therapies can help you make better decisions about your treatment plan.

Source: globenewswire.com